Hepatitis B vaccination in a school age population: A feasibility study

Journal of Medical Virology

Volumn 76, Issue 1, 2005, Pages 47-54

  Zuckerman, Jane ^a   Langer, Barbara ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Anti Hbs; Hepatitis b vaccination; Universal immunization

Indexed keywords

HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; RECOMBINANT HEPATITIS B VACCINE;

ADOLESCENT; ADOLESCENT DISEASE; ARTICLE; ENDEMIC DISEASE; FLU LIKE SYNDROME; HEPATITIS B VIRUS; HUMAN; NUTRITIONAL REQUIREMENT; PATIENT COMPLIANCE; POPULATION RESEARCH; SCHOOL CHILD; UNITED KINGDOM; VACCINATION;

ADOLESCENT; CHILD; DRUG ADMINISTRATION SCHEDULE; FEASIBILITY STUDIES; GREAT BRITAIN; HEALTH POLICY; HEPATITIS B; HEPATITIS B VACCINES; HUMANS; SCHOOLS; VACCINATION; VACCINES, SYNTHETIC;

HEPATITIS B VIRUS;

EID: 15944399690     PISSN: 01466615     EISSN: None     Source Type: Journal    
DOI: 10.1002/jmv.20335     Document Type: Article

References (62)

1. Aggarwal R, Ranjan P. 2004. Preventing and treating hepatitis B infection. BMJ 329:1080-1086.
2. Alter MJ. 2003a. Epidemiology of hepatitis B in Europe and worldwide. J Hepatol 39:64-69.
3. Alter MJ. 2003b. Epidemiology and prevention of hepatitis B. Semin Liver Dis 23:39-46.
4. Aweis D, Brabin BJ, Beeching NJ, Bunn JE, Cooper C, Gardner K, Iriyagolle C, Hart CA. 2001. Hepatitis B prevalence and risk factors for HBsAg carriage amongst Somali households in Liverpoool. Commun Dis Public Health 4:247-252.
5. Balogun MA, Ramsay ME, Fairley CK, Collins M, Heptonstall J. 1999. Acute hepatitis B infection in England and Wales: 1985-1996. Epidemiol Infect 122:125-131.
6. Banatvala JE, Van Damme P. 2003. Hepatitis B vaccine - do we need boosters? J Viral Hepat 10:1-6.
7. Banatvala J, Van Damme P, Oehen S. 2001. Lifelong protection against hepatitis B: The role of vaccine immunogenicity in immune memory. Vaccine 19:877-885.
8. Beeching NJ. 2004. Hepatitis B infection. Universal immunisation should be preferred in Britain. BMJ 329:1059-1060.
9. Beutels P. 2001. Economic evaluations of hepatitis B immunization: A global review of recent studies (1994-2000). Health Econ 10:751-774.
10. Boland G, Beran J, Lievens M, Sasadeusz J, Dentico P, Nothdurft H, Zuckerman JN, Genton B, Steffen R, Loutan L, Van Hattum J, Stoffel M. 2004. Safety and immunogenicity profile of an experimental hepatitis B vaccine adjuvanted with AS04. Vaccine 233: 16-32.
11. Boxall E, Skidmore S, Evans C, Nightingale S. 1994. The prevalence of hepatitis B and hepatitis C in an antenatal population of various ethnic origins. Epidemiol Infect 113:523-528.
12. Boxall EH, A Sira J, El-Shuhkri N, Kelly DA. 2004. Long-term persistence of immunity to hepatitis B after vaccination during infancy in a country where endemicity is low. J Infect Dis 190:1264-1269.
13. Brabin B, Beeching NJ, Bunn JEG, Cooper C, Gardner K, Hart CA. 2002. Hepatitis B prevalence among Somali households in Liverpool. Arch Dis Child 86:67-68.
14. CDR Weekly, 2004. Vol 14 no 39.
15. Chadha MS, Arankalla VA. 2000. Ten-year serological follow-up of hepatitis B vaccine recipients. Ind J Gastroenterol 19:168-171.
16. Craine N, Walker AM, Williamson S, Brown A, Hope VD. 2004. Hepatitis B and hepatitis C seroprevalence and risk behaviour among community-recruited drug injectors in North West Wales. Commun Dis Public Health 7:216-219.
17. Department of Health, Welsh Office, Scottish Office Department of Health, DHSS (Northern Ireland). 1996. Immunisation against Infectious Disease. London: HMSO.
18. Edmunds WJ. 1998. Universal or selective immunisation against hepatitis B virus in the United Kingdom? A review of recent cost-effectiveness studies. Commun Dis Public Health 1:221-228.
19. European Consensus Group on Hepatitis B Immunity. 2000. Are booster immunizations needed for lifelong hepatitis B immunity? Lancet 355:561-565.
20. Fagnani F, Le Fur C, Durnad I, Gibergy M. 2004. Economic evaluation of a combined DTPa, hepatitis B, polio, Hib vaccine. Potential impact of the introduction of Infanrix-Hexa in the French childhood immunisation schedule. Eur J Health Econ 5:143-149.
21. Fenn P, Gray A, Mcguire A. 1996. An economic evaluation of universal vaccination against hepatitis B virus. J Infect 32:197-204.
22. Gabutti G, Zepp F, Schuerman L, Dentico P, Bamfi R, Soncini R, Habermehl P, Knuf M, Crovari P. 2004. Evaluation of the immunogenicity and reactogenicity of a DTPa-HBV-IPV combination vaccine co-administered with a Hib conjugate vaccine either as a single injection of a hexavalent combination or as two separate injections at 3, 5 and 11 months of age. Scand J Infect Dis 36:585-592.
23. Gay NJ, Hesketh LM, Osborne KP, Farrington CP, Morgan-Capner P, Miller E. 1999. The prevalence of hepatitis B infection in adults in England and Wales. Epidemiol Infect 122:133-138.
24. Gesemann M, Scheiermann N. 1995. Quantification of hepatitis B vaccine-induced antibodies as a predictor of anti-HBs persistence. Vaccine 13:443-447.
25. Gilson RJ, de Ruiter A, Waite J, Ross E, Loveday C, Howell DR. 1998. Hepatitis B virus infection in patients attending a genitourinary medicine clinic: Risk factors and vaccine coverage. Sex Transm Infect 74:110-115.
26. Goldberg D, McMenamin J. 1998. The United Kingdom's hepatitis B immunisation strategy - where now? Commun Dis Public Health 1:79-83.
27. Goldstein ST, Cassidy WM, Hodgson W, Mahoney FJ. 2001. Factors associated with student participation in a school-based hepatitis B immunization program. J Sch Health 71:184-187.
28. Hahne S, Ramsay M, Soldan K, Balogun K, Mortimer P. 2003. Hepatitis B incidence among South Asian children in England and Wales: Implications for immunisation policy. Arch Dis Child 88:1082-1083.
29. Hahne S, Ramsay M, Balogun K, Edmunds WJ, Mortimer P. 2004. Incidence and routes of transmission of hepatitis B virus in England and Wales, 1995-2000: Implications for immunisation policy. J Clinical Virol 29:211-220.
30. Hesketh LM, Rowlatt JD, Gay NJ, Morgan-Capner P, Miller E. 1997. Childhood infection with hepatitis A and B viruses in England and Wales. Commun Dis Rep 7:60-63.
31. Jilg W, Van Damme P. 2004. Editorial - universal immunisation. Viral Hepatitis 13:1.
32. Jilg W, Schmidt M, Zachoval R, Deinhardt F. 1994. Hepatitis B vaccination: How long does protection last? Lancet 2:458.
33. Kane M. 1995. Global programme for control of hepatitis B infection. Vaccine 13:47-49.
34. Kawsar M, Goh BT. 2002. Hepatitis B virus infection among Chinese residents in the United Kingdom. Sex Transm Infect 78:166-168.
35. Lamagni TL, Hope VD, Davison KL, et al. 2001. Failure to vaccinate injecting drug users against hepatitis B in England and Wales. Commun Dis Public Health 4:71-72.
36. Lee PI, Lee CY, Huang LM, Chang MH. 1995. Long term efficacy of recombinant hepatitis B vaccine and risk of infection in infants borne to mothers with hepatitis B e antigen. Pediatrics 126:716-721.
37. Liu HB, Meng ZO, Ma JC, Han CO, Zhang YL, King ZC, Zhang YW, Liu YZ, Cao HL. 2000. A 12 year cohort study on the efficacy of plasma-derived hepatitis B vaccine in rural newborns. World J Gastroenterol 6:239-243.
38. Mangtani P, Hall AJ, Normand CE. 1999. Hepatitis B vaccination: The cost effectiveness of alternative strategies in England and Wales. Epidemiol Infect 122:133-138.
39. Mortimer PP, Miller E. 1997. Commentary: Antenatal screening and targeting should be sufficient in some countries (comment). BMJ 314:1036-1037.
40. Namgyal P. 2002. Impact of hepatitis B immunization in Europe and worldwide. European Association for the Study of the Liver. Consensus Conference on hepatitis B. Geneva, September 12-14.
41. NHS Executive. 1998. Screening of pregnant women for hepatitis B and immunization of babies at risk. Department of Health(HSC 1998/127).
42. Ramsay M, Gay N, Balogun K, Collins M. 1998. Control of hepatitis B in the United Kingdom. Vaccine 16:52-55.
43. Soldan K, Gay NJ, Allain JP, Llewelyn C, Jones C, Reeves J, Ramsay M. 2000. The prevalence of hepatitis B infection in adults with no recognized increased risk of infection. J Infect 41:198-199.
44. Swennen B, Levy J. 2004. Hexavalent combined vaccination. Rev Med Brux 25:A212-A218.
45. Van Damme P, Kane M, Meheus A (on behalf of the Viral Hepatitis Prevention Board). 1997. Integration of hepatitis B vaccination into national immunisation programmes. BMJ 314:1033-1037.
46. Vellinga A, Van Damme P, Bruckers L, Weyler JJ, Molenberghs G, Meheus A. 1999. Modelling long-term persistence of hepatitis B antibodies after vaccination. J Med Virol 57:100-103.
47. Wainwright RB, Bulkow LR, Parkinson AJ, Zanis C, McMahon BJ. 1997. Protection provided by hepatitis B vaccine in a Yupik Eskimo population: Results of a 10-year study. J Infect Dis 175: 674-677.
48. Wallace LA, Bramley JC, Ahmed S, Duff R, Hutchinson SJ, Carman WF, Kitchin NRE, Goldberg DJ. 2004. Determinants of universal adolescent hepatitis B vaccine uptake. Arch Dis Child 89:1041-1042.
49. West DJ. 1989. Clinical experience with hepatitis B vaccines. Am J Infect Contr 17:172-180.
50. West DJ, Calandra GB. 1996. Vaccine induced immunologic memory for hepatitis B surface antigen: Implications for policy on booster vaccination. Vaccine 14:1019-1027.
51. West DJ, Watson B, Lichtman J, Hesley TM, Hedberg K. 1994. Persistence of immunologic memory for twelve years in children given hepatitis B vaccine in infancy. Ped Infect Dis J 13:745-747.
52. Whittle H, Jaffar S, Wansbrough M, Mendy M, Dumpis U, Collinson A, Hall A. 2002. Observational study of vaccine efficacy 14 years after trial of hepatitis B vaccination in Gambian children. BMJ 325:569-573.
53. WHO. 2000. Expert review of methods for estimating hepatitis B disease burden. Geneva: WHO. pp 30-31.
54. Williams JR, Nokes DJ, Anderson RM. 1996a. Targeted hepatitis B vaccination - a cost effective immunisation strategy for the UK? J Epidemiol Community Health 50:667-673.
55. Williams JR, Nokes DJ, Medley GF, Anderson RM. 1996b. The transmission dynamics of hepatitis B in the UK: A mathematical model for evaluating costs and effectiveness of immunisation programmes. Epidemiol Infect 116:71-89.
56. World Health Organisation. 1992. Expanded Programme on Immunization global advisory group. Weekly Epidemiol Record 67:11-16.
57. World Health Organisation. 2004. Vaccine preventable diseases and Immunization Programme. Programme Report and Future Initiatives 2001-2005. WHO Regional Office for Europe, Copenhagen, (unpublished document).
58. Zuckerman AJ. 1996a. Developing new hepatitis B immunization strategies. Gut 38:60-62.
59. Zuckerman JN. 1996b. Non-response to hepatitis B vaccines and the kinetics of anti-HBs production. J Med Virol 50:283-288.
60. Zuckerman JN. 2000. Editorial - The importance of injecting vaccines into muscle. BMJ 321:1237-1238.
61. Zuckerman JN. 2003. The place of accelerated schedules for hepatitis A & B vaccinations. Drugs 63:1779-1784.
62. Zuckerman JN, Zuckerman AJ. 2002. Recombinant hepatitis B triple antigen vaccine: Hepacare. Expert Rev Vaccines 1:141-144.